Back to search results

ctDNA Testing for Endometrial Cancer Treatment Decisions

This study is looking at how a blood test called circulating tumor DNA (ctDNA) testing, specifically using the Natera SignateraTM test, can help doctors and patients make decisions about continuing treatment for advanced or recurrent endometrial cancer. This is for people whose cancer has specific genetic changes (MMR-D or MSI-H). After one year of standard chemotherapy and immune checkpoint inhibitor (ICI) treatment, you would have a ctDNA test. The study will then see how these results are used to decide if you should continue maintenance ICI treatment. Researchers will also track your health outcomes, like if you remain cancer-free. To join, you must have advanced or recurrent endometrial cancer with these specific genetic changes. The study aims to see if using ctDNA testing is practical.

Study design
This is an interventional study planning to enroll 30 women with endometrial cancer. The study does not specify a phase.
What's involved
You would have a blood draw for ctDNA testing at the 1-year mark. You and your doctors will complete surveys at different times, and you'll have an interview within 6 months of getting your 1-year ctDNA results.
Compensation
Not stated in the trial record.
Follow-up
The primary goal is to test the feasibility of ctDNA measured at 1 year. Health outcomes will also be looked at, but a specific follow-up duration is not mentioned.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07270666

ctDNA Testing to Inform Standard-of-Care Treatment Decisions in People With Endometrial Cancer

Recruiting
NAAges 18+InterventionalTreatment
Memorial Sloan Kettering Cancer Center
~30 participants
Updated 2026-07-13 on ClinicalTrials.gov
What's tested:ctDNA TestingBlood drawSurveysSemi-structured interviews

At a glance

Recruiting sites
7 of 7 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
will test the feasibility of ct-DNA
Measured over 1 year

Conditions

Endometrial Cancer

Explore related trials

Endometrial CarcinomaMRC1 wt AlleleMSI1 Gene

Where it's being run

7 sites across 2 states
New York4
New Jersey3

Study leadership

  • Ying Liu, MD, MPH · PRINCIPAL_INVESTIGATOR · Memorial Sloan Kettering Cancer Center

Who to contact

Ying Liu, MD, MPH
[email protected]
646-888-4946
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Patients must have pathologically confirmed endometrial cancer
Patients with advanced endometrial cancer
Stage III with residual disease
Stage IV
Recurrent endometrial cancer after adjuvant therapy only
Patients can have primary or planned interval surgery
MMR-D on immunohistochemistry OR MSI-H using any commercially available test
Patients with treated brain metastases are eligible if follow up brain imaging after CNS directed therapy shows no evidence of progression.
Eligible for standard of care chemotherapy with immune checkpoint inhibitor per treating investigator with no clinical contraindications
For the up to 10 patients who are allowed to enroll after C1D1 of standard of care treatments, they need to be on treatment with no clinical evidence of disease progression.
Patients may have received prior radiation therapy for treatment of endometrial cancer. Prior radiation therapy may have included pelvic radiation therapy, extended field pelvic/para aortic radiation therapy, intravaginal brachytherapy, and/or palliative radiation therapy.
Patients may have received prior hormonal therapy for treatment of endometrial cancer.
Patients may not have received prior therapy with an anti-PD-1, anti-PD-L1 or anti-CTLA-4 therapeutic antibody or other similar agents.
Except for the up to 10 patients who are allowed to enroll after C1D1 of standard of care treatments (chemotherapy and/or immune checkpoint inhibitors) per protocol.
Age ≥ 18
Not Pregnant and Not Nursing

What this trial measures

  • will test the feasibility of ct-DNA1 year

    informed de-escalation of standard of care ICI maintenance therapy defined as willingness of patients/providers to stop ICI therapy after 1 year in those with negative ctDNA testing.